Global Diabetes Therapeutics and Diagnostics

Diabetes Therapeutics and Diagnostics Comprehensive Study by Type (Injectable (Insulin, Amylinomimetic), Oral (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors)), Application (Hospitals, Clinics), Diabetes Type (Type1, Type2, Gestational Diabetes), Test Type (Fasting Plasma Glucose Test, Oral Glucose Tolerance Test, Hba1c Test) Players and Region - Global Market Outlook to 2030

Diabetes Therapeutics and Diagnostics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Diabetes Therapeutics and Diagnostics
Diabetes, scientifically known as diabetes mellitus, is a clinical condition in which a person has high blood sugar levels. It occurs due to the inefficiency of the pancreas in producing insulin (Type I) or the insensitivity of the body's cells to the insulin it produces (Type II), or both. Type II diabetes is common around the world due to increased obesity, urbanization, poor diet, and poor health conditions. The primary therapeutic for type 1 diabetes and a key player in type 2 management, insulin helps cells absorb glucose from the bloodstream, lowering blood sugar. It's administered through injections, pumps, or inhalers.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Diabetes Therapeutics and Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis Pharma AG (Switzerland), Owen Mumford Ltd. (United Kingdom), Palco Labs Inc. (United States), Novo Nordisk A/S (Denmark), Eli Lilly and Company (United States), Merck & Co. (United States), Abbott Laboratories (United States), Debiotech S.A. (Switzerland), Becton Dickinson (United States), Lifescan Inc. (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Inlight Solutions Inc. (United States), Terumo Corp. (Japan), Medtronic (Ireland), Animas Corp. (United States), Roche Holding AG (Switzerland) and Nipro Corp. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Takeda Pharmaceutical Co. Ltd. (Japan), Agamatrix Inc. (Germany), Sanofi (France) and Ascensia (United States).

Segmentation Overview
AMA Research has segmented the market of Global Diabetes Therapeutics and Diagnostics market by Type (Injectable [Insulin, Amylinomimetic] and Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors]), Application (Hospitals and Clinics) and Region.



On the basis of geography, the market of Diabetes Therapeutics and Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diabetes Type, the sub-segment i.e. Type1 will boost the Diabetes Therapeutics and Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test Type, the sub-segment i.e. Fasting Plasma Glucose Test will boost the Diabetes Therapeutics and Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Robust Economic Growth, And Sweeping Healthcare Reforms and An Increasing Prevalence of Common Health Disorders, Which Can Disable Patients and Potentially Lead To Fatal Health Complications

Market Growth Drivers:
The Growing Prevalence of Diabetes, Growth in Sedentary Lifestyle of People, Growing Older Population, A Rise in Unhealthy Diet and Increasing Levels of Physical Inactivity and High Incidences of Diabetes

Challenges:
Lack of Awareness among Patients towards the Availability of Diabetic Medications

Restraints:
Side Effects of Diabetic Drugs and Stringent Approval Process

Opportunities:
The Development of Affordable & Effective Diabetes Therapeutics and Growth in Awareness among People about Self-Management of Diabetes and Support from the Government

Market Leaders and their expansionary development strategies
On December 12, 2023, Medtronic and Dexcom announced a strategic partnership to develop and commercialize a next-generation CGM system. This collaboration combines Medtronic's expertise in insulin pump technology with Dexcom's G6 CGM sensor, aiming to provide seamless data integration and improved diabetes management.
On November 15, 2023, Tandem Diabetes unveiled its latest t:slim X2 insulin pump, featuring the advanced Control-IQ technology. This AI-powered system automatically adjusts insulin delivery based on real-time blood sugar readings and predicted trends, aiming to improve glycemic control and reduce the burden of diabetes management.


Key Target Audience
Providers of Diabetes Therapeutics and Diagnostics, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Injectable [Insulin, Amylinomimetic]
  • Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors]
By Application
  • Hospitals
  • Clinics
By Diabetes Type
  • Type1
  • Type2
  • Gestational Diabetes

By Test Type
  • Fasting Plasma Glucose Test
  • Oral Glucose Tolerance Test
  • Hba1c Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Prevalence of Diabetes
      • 3.2.2. Growth in Sedentary Lifestyle of People
      • 3.2.3. Growing Older Population
      • 3.2.4. A Rise in Unhealthy Diet and Increasing Levels of Physical Inactivity
      • 3.2.5. High Incidences of Diabetes
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among Patients towards the Availability of Diabetic Medications
    • 3.4. Market Trends
      • 3.4.1. Robust Economic Growth, And Sweeping Healthcare Reforms
      • 3.4.2. An Increasing Prevalence of Common Health Disorders, Which Can Disable Patients and Potentially Lead To Fatal Health Complications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetes Therapeutics and Diagnostics, by Type, Application, Diabetes Type, Test Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Diabetes Therapeutics and Diagnostics (Value)
      • 5.2.1. Global Diabetes Therapeutics and Diagnostics by: Type (Value)
        • 5.2.1.1. Injectable [Insulin, Amylinomimetic]
        • 5.2.1.2. Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors]
      • 5.2.2. Global Diabetes Therapeutics and Diagnostics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Diabetes Therapeutics and Diagnostics by: Diabetes Type (Value)
        • 5.2.3.1. Type1
        • 5.2.3.2. Type2
        • 5.2.3.3. Gestational Diabetes
      • 5.2.4. Global Diabetes Therapeutics and Diagnostics by: Test Type (Value)
        • 5.2.4.1. Fasting Plasma Glucose Test
        • 5.2.4.2. Oral Glucose Tolerance Test
        • 5.2.4.3. Hba1c Test
      • 5.2.5. Global Diabetes Therapeutics and Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Diabetes Therapeutics and Diagnostics (Price)
      • 5.3.1. Global Diabetes Therapeutics and Diagnostics by: Type (Price)
  • 6. Diabetes Therapeutics and Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis Pharma AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Owen Mumford Ltd. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Palco Labs Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novo Nordisk A/S (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Debiotech S.A. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Becton Dickinson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lifescan Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GlaxoSmithKline (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Inlight Solutions Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Terumo Corp. (Japan)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Medtronic (Ireland)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Animas Corp. (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Roche Holding AG (Switzerland)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Nipro Corp. (Japan)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Diabetes Therapeutics and Diagnostics Sale, by Type, Application, Diabetes Type, Test Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Diabetes Therapeutics and Diagnostics (Value)
      • 7.2.1. Global Diabetes Therapeutics and Diagnostics by: Type (Value)
        • 7.2.1.1. Injectable [Insulin, Amylinomimetic]
        • 7.2.1.2. Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors]
      • 7.2.2. Global Diabetes Therapeutics and Diagnostics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Diabetes Therapeutics and Diagnostics by: Diabetes Type (Value)
        • 7.2.3.1. Type1
        • 7.2.3.2. Type2
        • 7.2.3.3. Gestational Diabetes
      • 7.2.4. Global Diabetes Therapeutics and Diagnostics by: Test Type (Value)
        • 7.2.4.1. Fasting Plasma Glucose Test
        • 7.2.4.2. Oral Glucose Tolerance Test
        • 7.2.4.3. Hba1c Test
      • 7.2.5. Global Diabetes Therapeutics and Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Diabetes Therapeutics and Diagnostics (Price)
      • 7.3.1. Global Diabetes Therapeutics and Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetes Therapeutics and Diagnostics: by Type(USD Million)
  • Table 2. Diabetes Therapeutics and Diagnostics Injectable [Insulin, Amylinomimetic] , by Region USD Million (2018-2023)
  • Table 3. Diabetes Therapeutics and Diagnostics Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors] , by Region USD Million (2018-2023)
  • Table 4. Diabetes Therapeutics and Diagnostics: by Application(USD Million)
  • Table 5. Diabetes Therapeutics and Diagnostics Hospitals , by Region USD Million (2018-2023)
  • Table 6. Diabetes Therapeutics and Diagnostics Clinics , by Region USD Million (2018-2023)
  • Table 7. Diabetes Therapeutics and Diagnostics: by Diabetes Type(USD Million)
  • Table 8. Diabetes Therapeutics and Diagnostics Type1 , by Region USD Million (2018-2023)
  • Table 9. Diabetes Therapeutics and Diagnostics Type2 , by Region USD Million (2018-2023)
  • Table 10. Diabetes Therapeutics and Diagnostics Gestational Diabetes , by Region USD Million (2018-2023)
  • Table 11. Diabetes Therapeutics and Diagnostics: by Test Type(USD Million)
  • Table 12. Diabetes Therapeutics and Diagnostics Fasting Plasma Glucose Test , by Region USD Million (2018-2023)
  • Table 13. Diabetes Therapeutics and Diagnostics Oral Glucose Tolerance Test , by Region USD Million (2018-2023)
  • Table 14. Diabetes Therapeutics and Diagnostics Hba1c Test , by Region USD Million (2018-2023)
  • Table 15. South America Diabetes Therapeutics and Diagnostics, by Country USD Million (2018-2023)
  • Table 16. South America Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 17. South America Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 18. South America Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 19. South America Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 20. Brazil Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 21. Brazil Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 22. Brazil Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 23. Brazil Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 24. Argentina Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 25. Argentina Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 26. Argentina Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 27. Argentina Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 28. Rest of South America Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 29. Rest of South America Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 31. Rest of South America Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 32. Asia Pacific Diabetes Therapeutics and Diagnostics, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 34. Asia Pacific Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 36. Asia Pacific Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 37. China Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 38. China Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 39. China Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 40. China Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 41. Japan Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 42. Japan Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 43. Japan Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 44. Japan Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 45. India Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 46. India Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 47. India Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 48. India Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 49. South Korea Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 50. South Korea Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 51. South Korea Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 52. South Korea Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 53. Taiwan Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 54. Taiwan Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 55. Taiwan Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 56. Taiwan Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 57. Australia Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 58. Australia Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 59. Australia Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 60. Australia Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 65. Europe Diabetes Therapeutics and Diagnostics, by Country USD Million (2018-2023)
  • Table 66. Europe Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 67. Europe Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 68. Europe Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 69. Europe Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 70. Germany Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 71. Germany Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 72. Germany Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 73. Germany Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 74. France Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 75. France Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 76. France Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 77. France Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 78. Italy Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 79. Italy Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 80. Italy Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 81. Italy Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 82. United Kingdom Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 83. United Kingdom Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 84. United Kingdom Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 85. United Kingdom Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 86. Netherlands Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 87. Netherlands Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 88. Netherlands Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 89. Netherlands Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 90. Rest of Europe Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 91. Rest of Europe Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 92. Rest of Europe Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 93. Rest of Europe Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 94. MEA Diabetes Therapeutics and Diagnostics, by Country USD Million (2018-2023)
  • Table 95. MEA Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 96. MEA Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 97. MEA Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 98. MEA Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 99. Middle East Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 100. Middle East Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 101. Middle East Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 102. Middle East Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 103. Africa Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 104. Africa Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 105. Africa Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 106. Africa Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 107. North America Diabetes Therapeutics and Diagnostics, by Country USD Million (2018-2023)
  • Table 108. North America Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 109. North America Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 110. North America Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 111. North America Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 112. United States Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 113. United States Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 114. United States Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 115. United States Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 116. Canada Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 117. Canada Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 118. Canada Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 119. Canada Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 120. Mexico Diabetes Therapeutics and Diagnostics, by Type USD Million (2018-2023)
  • Table 121. Mexico Diabetes Therapeutics and Diagnostics, by Application USD Million (2018-2023)
  • Table 122. Mexico Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2018-2023)
  • Table 123. Mexico Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2018-2023)
  • Table 124. Diabetes Therapeutics and Diagnostics: by Type(USD/Units)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Diabetes Therapeutics and Diagnostics: by Type(USD Million)
  • Table 144. Diabetes Therapeutics and Diagnostics Injectable [Insulin, Amylinomimetic] , by Region USD Million (2025-2030)
  • Table 145. Diabetes Therapeutics and Diagnostics Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors] , by Region USD Million (2025-2030)
  • Table 146. Diabetes Therapeutics and Diagnostics: by Application(USD Million)
  • Table 147. Diabetes Therapeutics and Diagnostics Hospitals , by Region USD Million (2025-2030)
  • Table 148. Diabetes Therapeutics and Diagnostics Clinics , by Region USD Million (2025-2030)
  • Table 149. Diabetes Therapeutics and Diagnostics: by Diabetes Type(USD Million)
  • Table 150. Diabetes Therapeutics and Diagnostics Type1 , by Region USD Million (2025-2030)
  • Table 151. Diabetes Therapeutics and Diagnostics Type2 , by Region USD Million (2025-2030)
  • Table 152. Diabetes Therapeutics and Diagnostics Gestational Diabetes , by Region USD Million (2025-2030)
  • Table 153. Diabetes Therapeutics and Diagnostics: by Test Type(USD Million)
  • Table 154. Diabetes Therapeutics and Diagnostics Fasting Plasma Glucose Test , by Region USD Million (2025-2030)
  • Table 155. Diabetes Therapeutics and Diagnostics Oral Glucose Tolerance Test , by Region USD Million (2025-2030)
  • Table 156. Diabetes Therapeutics and Diagnostics Hba1c Test , by Region USD Million (2025-2030)
  • Table 157. South America Diabetes Therapeutics and Diagnostics, by Country USD Million (2025-2030)
  • Table 158. South America Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 159. South America Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 160. South America Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 161. South America Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 162. Brazil Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 163. Brazil Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 164. Brazil Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 165. Brazil Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 166. Argentina Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 167. Argentina Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 168. Argentina Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 169. Argentina Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 170. Rest of South America Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 171. Rest of South America Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 172. Rest of South America Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 173. Rest of South America Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 174. Asia Pacific Diabetes Therapeutics and Diagnostics, by Country USD Million (2025-2030)
  • Table 175. Asia Pacific Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 176. Asia Pacific Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 177. Asia Pacific Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 178. Asia Pacific Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 179. China Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 180. China Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 181. China Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 182. China Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 183. Japan Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 184. Japan Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 185. Japan Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 186. Japan Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 187. India Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 188. India Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 189. India Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 190. India Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 191. South Korea Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 192. South Korea Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 193. South Korea Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 194. South Korea Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 195. Taiwan Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 196. Taiwan Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 197. Taiwan Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 198. Taiwan Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 199. Australia Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 200. Australia Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 201. Australia Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 202. Australia Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 207. Europe Diabetes Therapeutics and Diagnostics, by Country USD Million (2025-2030)
  • Table 208. Europe Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 209. Europe Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 210. Europe Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 211. Europe Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 212. Germany Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 213. Germany Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 214. Germany Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 215. Germany Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 216. France Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 217. France Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 218. France Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 219. France Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 220. Italy Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 221. Italy Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 222. Italy Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 223. Italy Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 224. United Kingdom Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 225. United Kingdom Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 226. United Kingdom Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 227. United Kingdom Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 228. Netherlands Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 229. Netherlands Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 230. Netherlands Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 231. Netherlands Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 232. Rest of Europe Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 233. Rest of Europe Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 234. Rest of Europe Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 235. Rest of Europe Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 236. MEA Diabetes Therapeutics and Diagnostics, by Country USD Million (2025-2030)
  • Table 237. MEA Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 238. MEA Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 239. MEA Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 240. MEA Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 241. Middle East Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 242. Middle East Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 243. Middle East Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 244. Middle East Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 245. Africa Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 246. Africa Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 247. Africa Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 248. Africa Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 249. North America Diabetes Therapeutics and Diagnostics, by Country USD Million (2025-2030)
  • Table 250. North America Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 251. North America Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 252. North America Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 253. North America Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 254. United States Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 255. United States Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 256. United States Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 257. United States Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 258. Canada Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 259. Canada Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 260. Canada Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 261. Canada Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 262. Mexico Diabetes Therapeutics and Diagnostics, by Type USD Million (2025-2030)
  • Table 263. Mexico Diabetes Therapeutics and Diagnostics, by Application USD Million (2025-2030)
  • Table 264. Mexico Diabetes Therapeutics and Diagnostics, by Diabetes Type USD Million (2025-2030)
  • Table 265. Mexico Diabetes Therapeutics and Diagnostics, by Test Type USD Million (2025-2030)
  • Table 266. Diabetes Therapeutics and Diagnostics: by Type(USD/Units)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetes Therapeutics and Diagnostics: by Type USD Million (2018-2023)
  • Figure 5. Global Diabetes Therapeutics and Diagnostics: by Application USD Million (2018-2023)
  • Figure 6. Global Diabetes Therapeutics and Diagnostics: by Diabetes Type USD Million (2018-2023)
  • Figure 7. Global Diabetes Therapeutics and Diagnostics: by Test Type USD Million (2018-2023)
  • Figure 8. South America Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 10. Europe Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 11. MEA Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 12. North America Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 13. Global Diabetes Therapeutics and Diagnostics: by Type USD/Units (2018-2023)
  • Figure 14. Global Diabetes Therapeutics and Diagnostics share by Players 2023 (%)
  • Figure 15. Global Diabetes Therapeutics and Diagnostics share by Players (Top 3) 2023(%)
  • Figure 16. Global Diabetes Therapeutics and Diagnostics share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis Pharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis Pharma AG (Switzerland) Revenue: by Geography 2023
  • Figure 20. Owen Mumford Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Owen Mumford Ltd. (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Palco Labs Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Palco Labs Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 25. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 26. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 28. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 30. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 32. Debiotech S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Debiotech S.A. (Switzerland) Revenue: by Geography 2023
  • Figure 34. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Becton Dickinson (United States) Revenue: by Geography 2023
  • Figure 36. Lifescan Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Lifescan Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 39. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 40. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 42. Inlight Solutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Inlight Solutions Inc. (United States) Revenue: by Geography 2023
  • Figure 44. Terumo Corp. (Japan) Revenue, Net Income and Gross profit
  • Figure 45. Terumo Corp. (Japan) Revenue: by Geography 2023
  • Figure 46. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 47. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 48. Animas Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 49. Animas Corp. (United States) Revenue: by Geography 2023
  • Figure 50. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 51. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 52. Nipro Corp. (Japan) Revenue, Net Income and Gross profit
  • Figure 53. Nipro Corp. (Japan) Revenue: by Geography 2023
  • Figure 54. Global Diabetes Therapeutics and Diagnostics: by Type USD Million (2025-2030)
  • Figure 55. Global Diabetes Therapeutics and Diagnostics: by Application USD Million (2025-2030)
  • Figure 56. Global Diabetes Therapeutics and Diagnostics: by Diabetes Type USD Million (2025-2030)
  • Figure 57. Global Diabetes Therapeutics and Diagnostics: by Test Type USD Million (2025-2030)
  • Figure 58. South America Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 59. Asia Pacific Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 60. Europe Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 61. MEA Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 62. North America Diabetes Therapeutics and Diagnostics Share (%), by Country
  • Figure 63. Global Diabetes Therapeutics and Diagnostics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Novartis Pharma AG (Switzerland)
  • Owen Mumford Ltd. (United Kingdom)
  • Palco Labs Inc. (United States)
  • Novo Nordisk A/S (Denmark)
  • Eli Lilly and Company (United States)
  • Merck & Co. (United States)
  • Abbott Laboratories (United States)
  • Debiotech S.A. (Switzerland)
  • Becton Dickinson (United States)
  • Lifescan Inc. (United States)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline (United Kingdom)
  • Inlight Solutions Inc. (United States)
  • Terumo Corp. (Japan)
  • Medtronic (Ireland)
  • Animas Corp. (United States)
  • Roche Holding AG (Switzerland)
  • Nipro Corp. (Japan)
Additional players considered in the study are as follows:
Takeda Pharmaceutical Co. Ltd. (Japan) , Agamatrix Inc. (Germany) , Sanofi (France) , Ascensia (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 211 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetes Therapeutics and Diagnostics Quantitative research analysis
Global Diabetes Therapeutics and Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis Pharma AG (Switzerland), Owen Mumford Ltd. (United Kingdom), Palco Labs Inc. (United States), Novo Nordisk A/S (Denmark), Eli Lilly and Company (United States), Merck & Co. (United States), Abbott Laboratories (United States), Debiotech S.A. (Switzerland), Becton Dickinson (United States), Lifescan Inc. (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Inlight Solutions Inc. (United States), Terumo Corp. (Japan), Medtronic (Ireland), Animas Corp. (United States), Roche Holding AG (Switzerland) and Nipro Corp. (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Robust Economic Growth, And Sweeping Healthcare Reforms " is seen as one of major influencing trends for Diabetes Therapeutics and Diagnostics Market during projected period 2023-2030.
The Diabetes Therapeutics and Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Diabetes Therapeutics and Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Daptomycin Comprehensive Study by Type (350 mg lyophilized powder, 500 mg lyophilized powder), Application (Adult, Pediatric patients (1 to 17 years of age)), End -Users (Pharmaceuticals, Clinics, We...
$ 3500
Epistaxis Comprehensive Study by Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, Cauterizing Agents, Others), Application (Anterior Epistaxis, Posterior Epistaxis), Treatment (Medication, ...
$ 3650
Krabbe Disease Treatment Comprehensive Study by Type (Infantile (occurs in babies less than six months of age), Late-onset (can happen at any other time)), Diagnosed Test (Imaging Scans (MRI), Nerve ...
$ 3500
Tendinitis Treatment Comprehensive Study by Type (Medication (Pain Relievers, Corticosteroids, Platelet-rich plasma (PRP)), Physical Therapy, Surgery, Other Procedures (Dry needling, Ultrasonic treat...
$ 3750
Duodenal Cancer Comprehensive Study by Type (Adenocarcinoma, Sarcoma, Neuroendocrine Tumors, Lymphoma), Treatment (Surgery, Radiotherapy, Chemotherapy), Diagnosis (Colonoscopy, Capsule Endoscopy, Bar...
$ 3350
Epstein-Barr Virus Infections Treatment Comprehensive Study by Type (Apatinib Mesylate, AR-12, Baltaleucel-T, Others), Application (Hospital, Clinic, Ambulatory Surgery Centers, Others) Players and R...
$ 3500